Alkermes plc. (ALKS) stock
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30214% above fair value
$47.03+0.05 (+0.11%)
Close on Nov 13, 2026Market cap $7.89BP/E 123.8Yield –
Alkermes operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Alkermes's operating income for the twelve months ending Jun 30, 2026 was $117.26M, down 68.7% year over year. For fiscal 2025 it was $253.96M, down 39.6% from the year before. The highest annual figure on record is $420.64M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $253.96M | -39.6% |
| FY2024 | Dec 31, 2024 | $420.64M | +1.6% |
| FY2023 | Dec 31, 2023 | $414.12M | – |
| FY2022 | Dec 31, 2022 | -$6.09M | -106.2% |
| FY2021 | Dec 31, 2021 | $97.75M | – |
| FY2020 | Dec 31, 2020 | -$112.43M | – |
| FY2019 | Dec 31, 2019 | -$175.48M | – |
| FY2018 | Dec 31, 2018 | -$99.13M | – |
| FY2017 | Dec 31, 2017 | -$147.90M | – |
| FY2016 | Dec 31, 2016 | -$208.67M | – |
| FY2015 | Dec 31, 2015 | -$224.30M | -374.2% |
| FY2013 | Mar 31, 2013 | $81.81M | – |
| FY2012 | Mar 31, 2012 | -$88.28M | – |
| FY2011 | Mar 31, 2011 | -$45.63M | – |
| FY2010 | Mar 31, 2010 | -$43.03M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.35M | -80.3% |
| Q1 FY2026 | Mar 31, 2026 | -$48.28M | -450.1% |
| Q4 FY2025 | Dec 31, 2025 | $58.10M | -64.3% |
| Q3 FY2025 | Sep 30, 2025 | $89.08M | -15.0% |
| Q2 FY2025 | Jun 30, 2025 | $92.98M | -15.4% |
| Q1 FY2025 | Mar 31, 2025 | $13.79M | -68.2% |
| Q4 FY2024 | Dec 31, 2024 | $162.69M | +197.8% |
| Q3 FY2024 | Sep 30, 2024 | $104.76M | +17.4% |
| Q2 FY2024 | Jun 30, 2024 | $109.88M | -60.9% |
| Q1 FY2024 | Mar 31, 2024 | $43.31M | – |
| Q4 FY2023 | Dec 31, 2023 | $54.63M | -52.7% |
| Q3 FY2023 | Sep 30, 2023 | $89.19M | – |
| Q2 FY2023 | Jun 30, 2023 | $281.27M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.97M | – |
| Q4 FY2022 | Dec 31, 2022 | $115.59M | -10.7% |
| Q3 FY2022 | Sep 30, 2022 | -$60.64M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.46M | -879.4% |
| Q1 FY2022 | Mar 31, 2022 | -$26.59M | – |
| Q4 FY2021 | Dec 31, 2021 | $129.42M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.66M | – |
| Q2 FY2021 | Jun 30, 2021 | $4.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$30.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$37.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.93M | -49770.0% |
| Q3 FY2019 | Sep 30, 2019 | -$53.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.92M | – |
| Q1 FY2019 | Mar 31, 2019 | -$76.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $20.00K | -99.7% |
| Q3 FY2018 | Sep 30, 2018 | -$37.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$102.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$61.89M | – |
| Q4 FY2017 | Dec 31, 2017 | $5.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$38.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$44.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$70.87M | – |
| Q4 FY2016 | Dec 31, 2016 | -$23.54M | – |
| Q3 FY2016 | Sep 30, 2016 | -$61.13M | – |
See a number that looks wrong?